Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
STRATA Skin Sciences (NASDAQ: SSKN) highlighted a first English-language case study (Case Rep Oncol 2025;18:325–329) reporting successful use of the 308-nm excimer (XTRAC) laser to treat poikilodermatous mycosis fungoides (pMF), a rare cutaneous T‑cell lymphoma subtype. A 50-year-old patient received 1,250 mJ/cm² over five sessions with topical corticosteroids and showed marked improvement with near-complete lesion resolution at three months. The release cites a 2023 systematic review (14 studies, 72 patients) reporting 73.6% complete clinical response and low relapse (5.7% at mean 13 months) for 308-nm excimer therapy, arguing for a targeted alternative to whole-body phototherapies and noting ongoing reimbursement engagement with CMS.
STRATA Skin Sciences (NASDAQ: SSKN) ha evidenziato un primo studio di caso in lingua inglese (Case Rep Oncol 2025;18:325–329) che riporta l'uso riuscito del laser a excimer 308-nm (XTRAC) per trattare la micosi fungoide poikilodermica (pMF), una rara sottotipologia di linfoma cutaneo a cellule T. Un paziente di 50 anni ha ricevuto 1.250 mJ/cm² in cinque sessioni con corticosteroidi topici e ha mostrato un notevole miglioramento con quasi totale risoluzione delle lesioni a tre mesi. Il comunicato cita una revisione sistematica del 2023 (14 studi, 72 pazienti) che riporta 73,6% di risposta clinica completa e bassa ricaduta (5,7% in media a 13 mesi) per la terapia con excimer 308-nm, sostenendo un'alternativa mirata alle phototerapie su tutto il corpo e rilevando un continuo impegno di rimborso con CMS.
STRATA Skin Sciences (NASDAQ: SSKN) destacó un primer estudio de caso en inglés (Case Rep Oncol 2025;18:325–329) que reporta el uso exitoso del láser excimér de 308 nm (XTRAC) para tratar la micosis fungoide poikilodérmica (pMF), una rara variante de linfoma cutáneo de células T. Un paciente de 50 años recibió 1.250 mJ/cm² en cinco sesiones con corticosteroides tópicos y mostró una mejoría marcada con resolución casi completa de las lesiones a los tres meses. El comunicado cita una revisión sistemática de 2023 (14 estudios, 72 pacientes) que reporta 73,6% de respuesta clínica completa y baja recaída (5,7% en promedio a 13 meses) para la terapia con excímer de 308 nm, argumentando a favor de una alternativa dirigida a las fototerapias de cuerpo entero y señalando un compromiso continuo de reembolso con CMS.
STRATA Skin Sciences (나스닥: SSKN)은 영어로 된 첫 사례 연구(Case Rep Oncol 2025;18:325–329)을 강조하며 308-nm 엑시머(XTRAC) 레이저를 이용한 포이클로더마토스 마이코시스(pMF) 치료의 성공 사례를 보고했다. 이는 피부 T세포 림프종의 드문 아형이다. 50세 환자는 5회에 걸쳐 1,250 mJ/cm²를 받고 국소 코르티코스테로이드를 병용했고, 3개월 만에 병변이 거의 완전히 해소될 정도로 뚜렷한 개선을 보였다. 이 발표는 2023년의 체계적 고찰(14개 연구, 72명)을 인용하며 308-nm 엑시머 치료의 임상적 완전 반응율 73.6%과 재발이 낮은(평균 13개월 시점 5.7%) 것을 보고하여, 전신 광치료에 대한 표적 대안을 제시하고 CMS와의 상환 협상 지속 여부를 주목한다.
STRATA Skin Sciences (NASDAQ : SSKN) a mis en évidence une première étude de cas en anglais (Case Rep Oncol 2025;18:325–329) rapportant l’utilisation réussie du laser excimér 308 nm (XTRAC) pour traiter la mycosis fungoïde poikilodermique (pMF), une sous-type rare de lymphome cutané de cellules T. Un patient de 50 ans a reçu 1 250 mJ/cm² sur cinq séances avec des corticostéroïdes topiques et a montré une amélioration marquée avec une résolution quasi complète des lésions à trois mois. Le communiqué cite une revue systématique de 2023 (14 études, 72 patients) qui rapporte 73,6% de réponse clinique complète et une faible récidive (5,7% en moyenne à 13 mois) pour la thérapie à l’excimer 308 nm, défendant une alternative ciblée aux photothérapies corporelles et notant l’engagement continu sur le remboursement avec le CMS.
STRATA Skin Sciences (NASDAQ: SSKN) hob eine erste englischsprachige Fallstudie hervorgehoben (Case Rep Oncol 2025;18:325–329), die den erfolgreichen Einsatz des 308-nm Excimer-Lasers (XTRAC) zur Behandlung der poikilodermatösen Mycosis fungoides (pMF), einer seltenen Unterform des kutanen T-Zell-Lymphoms, berichtet. Ein 50-jähriger Patient erhielt 1.250 mJ/cm² über fünf Sitzungen in Kombination mit topischen Kortikosteroiden und zeigte drei Monate nach der Behandlung eine deutliche Verbesserung mit nahezu vollständiger Auflösung der Läsionen. Die Veröffentlichung zitiert eine systematische Übersichtsarbeit von 2023 (14 Studien, 72 Patienten), die 73,6% vollständige klinische Ansprechrate und eine geringe Rückfallrate (5,7% im Durchschnitt nach 13 Monaten) für die 308-nm Excimer-Therapie angibt und eine zielgerichtete Alternative zu Ganzkörperphototherapien betont sowie darauf hinweist, dass CMS weiter an der Erstattung arbeitet.
STRATA Skin Sciences (بورصة ناسداك: SSKN) أبرزت أول دراسة حالة باللغة الإنجليزية (Case Rep Oncol 2025;18:325–329) تُفيد بالتجربة الناجحة لاستخدام جهاز الليزر Excimer 308-nm (XTRAC) لعلاج المايسك الفانجرويد Poikilodermatous mycosis fungoides (pMF)، وهو نوع نادر من ليمفوما البشرة من فئة T. تلقّى المريض البالغ من العمر 50 عامًا 1,250 مJ/cm² على خمس جلسات مع الكورتيكوستيرويدات الموضعية وأظهر تحسنًا ملحوظًا مع حلّ شبه كامل للآفات لدى ثلاثة أشهر. وتستشهد النشرة بمراجعة منهجية من 2023 (14 دراسة، 72 مريضًا) تشير إلى 73.6% استجابة إكلينيكية كاملة وانخفاض التكرار (5.7% بمتوسط 13 شهرًا) للعلاج بـ Excimer 308-nm، مع تعزيز خيار مستهدف عن phototherapies للجسم كله وذكر استمرار التزام CMS بالتغطية/التعويضات.
STRATA Skin Sciences（纳斯达克：SSKN） 强调了一项首次英文病例研究（Case Rep Oncol 2025;18:325–329），报告使用308-nm Excimer（XTRAC）激光治疗点状萎缩型真菌样皮病（poikilodermatous mycosis fungoides，pMF），这是一种罕见的皮肤T细胞淋巴瘤亚型。50岁患者在五次治疗中使用了1,250 mJ/cm²，并联合局部糖皮质激素治疗，三个月时病变几乎完全消退，显示出显著改善。该报道引述了2023年的系统综述（14项研究，72名患者），报告为
308-nm Excimer治疗的临床完全缓解率为73.6%，复发率较低（平均13个月时为5.7%），认为这是对全身光疗的有针对性替代，并指出CMS在报销方面的持续沟通。
- First English-language pMF case showing lesion resolution
- Patient improvement after 5 sessions at 1,250 mJ/cm²
- Systematic review: 73.6% complete clinical response (72 patients)
- Low relapse rate: 5.7% after mean 13 months (review)
- Single-case report limits generalizability of pMF result
- Durability beyond three months not demonstrated in this case
Insights
308‑nm excimer laser shows a documented lesion-level response in pMF and supports broader reimbursement tailwinds.
The case report documents a 50‑year‑old patient with poikilodermatous mycosis fungoides who received 1,250 mJ/cm2 over five sessions of a 308‑nm excimer laser plus topical corticosteroids and had marked improvement by three months, with near complete resolution of erythema. This adds a lesion‑targeted, localized option to the treatment toolkit for patch‑stage CTCL variants and aligns with prior pooled evidence showing high complete response rates for excimer therapy (
Key dependencies and risks include single‑patient evidence and the combination with topical steroids, which limits attribution of effect to laser alone. The report cites expanded CMS reimbursement codes as a material commercial enabler; reimbursement clarity and broader, multicenter confirmations remain required for durable uptake. Watch for replication in larger cohorts, formal prospective studies, and CMS policy updates; expect meaningful clinical and commercial signals within
First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company’s XTRAC capability to address the condition
HORSHAM, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces a groundbreaking clinical case study published in Case Reports in Oncology. The study reports the successful use of 308-nm excimer laser to treat a rare and under-recognized form of cutaneous T-cell lymphoma, mycosis fungoides (MF) through a subtype called poikilodermatous mycosis fungiodes (pMF).
Led by dermatology researchers at Tohoku University Graduate School of Medicine, the newly published, peer reviewed study (Case Rep Oncol 2025;18:325–329) represents a first-of-its-kind English-language report validating excimer laser therapy as a safe and effective option for this difficult-to-treat condition.
Dr. Dolev Rafaeli, Strata President and CEO, commented, “The XTRAC Excimer laser continues to draw attention worldwide for its versatility in treating inflammatory skin conditions. It is that versatility, both in monotherapy and in combination with multiple medications, that has resulted in the Centers for Medicare and Medicaid Services (CMS) significantly expanding the reimbursement codes for a much wider variety of these conditions, including MF and pMF as outlined in this study, as well as every autoimmune-based skin condition. It is important to note that independent investigators continue testing the limits of XTRAC therapy, and publication after publication verifies the clinical track record of the device, whether in patients in the U.S. or worldwide. It is worth noting that Japan, where this study was conducted, is a significant market for the XTRAC Excimer laser as dermatologists there are at the cutting edge of pioneering new uses for the technology. We continue to work closely with CMS in obtaining the expanded reimbursement for XTRAC and will continue to provide updates as they develop.”
The study was conducted by Dr. Manami Watanabe, Dr. Taku Fujimura, and Dr. Yoshihide Asano, all faculty members in the Department of Dermatology at Tohoku University, one of Japan’s leading national universities. The institution is globally recognized for excellence in biomedical research and dermatologic innovation, with a robust clinical and translational research program focused on autoimmune and lymphoproliferative skin diseases.
In 2022, the International Journal of Dermatology published a detailed systematic review assessing the efficacy and safety of the 308-nm excimer laser in the treatment of mycosis fungoides (MF) (International Journal of Dermatology 2023, 62, e54–e104). The review included 14 studies encompassing 72 patients. Patients received an average of 18.7 treatment sessions (range 6–44) with a mean cumulative dose of approximately 5 J/cm². Overall,
Understanding the Disease: Mycosis Fungoides and the Poikilodermatous Subtype
Mycosis fungoides (MF) is the most prevalent form of cutaneous T-cell lymphoma (CTCL), a rare malignancy that affects the skin’s immune T cells. In the United States, MF occurs at a rate of approximately 4–6 new cases per million person-years, with a prevalence of 5.2–6.6 per 100,000 persons, according to data from SEER and the National Cancer Database.1 MF is more common in males, with a male-to-female ratio of approximately 1.4–2:1, and more frequently affects African American patients, who also tend to present at younger ages and with more advanced disease.2
Case Study Results: Excimer Laser Shows Rapid Clinical Response
The case involved a 50-year-old female with a 3-year history of progressive reticulated pigmentation and atrophic macules on the left thigh. Despite prolonged treatment with topical corticosteroids and vitamin D analogs, the lesions had steadily progressed. A biopsy and immunohistochemistry confirmed a diagnosis of poikilodermatous MF.
Treatment was initiated with a 308-nm excimer laser, delivering 1,250 mJ/cm² of energy over five sessions, in combination with topical corticosteroids. After three months, the patient exhibited marked clinical improvement, with complete resolution of erythema and only minimal pigmentation remaining.3
This is the first English-language report to document the successful treatment of pMF using 308-nm excimer laser, highlighting both its safety and efficacy in localized, patch-stage MF—a setting where traditional therapies often carry greater systemic risks.
Why Excimer Laser Therapy Matters
While narrowband UVB (NB-UVB) and psoralen plus UVA (PUVA) are standard treatments for early MF, they require whole-body exposure, carry cumulative dose concerns, and can be impractical for patients with localized disease. The excimer laser, by contrast, emits high-intensity, targeted UVB light (308 nm), allowing clinicians to treat specific lesions while sparing unaffected skin.4
Additionally, the energy density of the excimer laser exceeds that of conventional UV therapy, potentially enhancing therapeutic effects in lesions that are treatment-resistant or thickened.5
Its clinical utility has been previously demonstrated in vitiligo, alopecia areata, psoriasis, and early-stage MF, but this is the first formal application and publication in pMF.6
Conclusion
This case adds to the growing evidence base for the excimer laser as a front-line modality in early-stage or treatment-resistant CTCL variants, offering a targeted, safe, and efficacious alternative to systemic or full-body phototherapy. Future studies and broader clinical application could significantly impact treatment guidelines and improve patient quality of life in this rare disease population.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, tariffs, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
1 SEER & NCDB analysis – PMCID: PMC9128921
2 Demographic disparities in MF – JAAD 2017
3 Watanabe M, Fujimura T, Asano Y. Case Rep Oncol 2025;18:325–329. DOI: 10.1159/000544164
4 Olsen EA et al., USCL Consortium phototherapy guidelines – JAAD 2016
5 Meisenheimer JL, Excimer laser in MF – Dermatol Online J 2006;12(7):11
6 Passeron et al., Excimer efficacy in MF – Arch Dermatol 2004;140(10):1291–3
FAQ
What did STRATA (SSKN) announce on October 14, 2025 about XTRAC and pMF?
How was the patient treated in the 2025 pMF case using XTRAC?
What clinical evidence did STRATA cite about 308-nm excimer efficacy for mycosis fungoides?
Does the October 14, 2025 release mention reimbursement developments for XTRAC (SSKN)?
How does excimer laser compare to whole-body phototherapy for localized MF according to the release?
What are the limitations of the pMF case report for investors evaluating SSKN clinical progress?
